RxDoctor Payments Data

Modeanna Wade, APRN

Family · Memphis, TNNPI 1760767016

Payments from drug & device makers

$504in general payments, 2019–2025

Across 29 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$99
  • Otsuka America Pharmaceutical, Inc.$76
  • AstraZeneca$68
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Boehringer Ingelheim$40
  • Abiomed$27
  • plus $134 from 8 others

What the payments were for

  • Food & beverage$504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$504 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,716
Medicare patients
98
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$111,340
OzempicSemaglutide67$69,504
TrulicityDulaglutide49$54,621
FarxigaDapagliflozin Propanediol52$41,710
RexultiBrexpiprazole26$35,691
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$33,973
LinzessLinaclotide40$30,946
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$29,159
JanuviaSitagliptin Phosphate23$22,278
EliquisApixaban27$21,971
JardianceEmpagliflozin19$18,346
BrilintaTicagrelor16$11,627
Spiriva RespimatTiotropium Bromide14$10,440
XareltoRivaroxaban12$10,324
Janumet XrSitagliptin Phos/Metformin Hcl11$8,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$68$89,478138 claims
Otsuka America Pharmaceutical, Inc.Rexulti$76$35,69126 claims
GSKTrelegy Ellipta$99$33,97332 claims
AbbVieLinzess$22$30,94640 claims
Boehringer IngelheimJardiance, Spiriva Respimat$40$28,78633 claims
PfizerEliquis$24$21,97127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →